Heart Failure

A roundup of the biggest cardiology news out of ESC Congress on day 1, spanning new guidelines, a phase 3 miss, and 2 practice-informing trial readouts.

The updated ESC guidelines make sweeping changes to HF terminology, eliminating HFmrEF and recategorizing acute HF for patients with slower symptom development.

A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

Ronald D'Agostino, DO, discusses the 2026 HFpEF pathway, H2FPEF screening, and comorbidity-first heart failure care.

A pair of clinical forums examined new CKM staging, SGLT2 and MRA trial data, and the barriers delaying heart failure treatment.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

Phase 3 LEVEL trial of TNX-103 missed its primary 6MWD endpoint in PH-HFpEF, though a sicker patient subgroup showed benefit versus placebo.

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he discusses upcoming advancements in heart failure care.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he walks through his long and successful career in cardiology.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Chiadi Ndumele, MD, PhD, breaks down the new guidelines and how they should be implemented in this sweeping document.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

Javed Butler, MD, MBA, discusses how aldosterone synthase inhibition could shift treatment across heart failure, CKD, and resistant hypertension.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

FDA De Novo classification clears Cardiosense PCWP Analysis Software to estimate filling pressures in selected adults with HFrEF.